KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) FCF Margin (2017 - 2026)

Twist Bioscience has reported FCF Margin over the past 10 years, most recently at 11.85% for Q1 2026.

  • Quarterly FCF Margin rose 127.0% to 11.85% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 21.44% through Mar 2026, down 407.0% year-over-year, with the annual reading at 20.08% for FY2025, 202.0% up from the prior year.
  • FCF Margin was 11.85% for Q1 2026 at Twist Bioscience, up from 33.55% in the prior quarter.
  • Over five years, FCF Margin peaked at 5.84% in Q3 2023 and troughed at 154.4% in Q1 2022.
  • The 5-year median for FCF Margin is 26.59% (2024), against an average of 45.94%.
  • Year-over-year, FCF Margin crashed -4881bps in 2022 and then surged 9756bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 121.48% in 2022, then soared by 72bps to 34.24% in 2023, then increased by 22bps to 26.56% in 2024, then fell by -26bps to 33.55% in 2025, then skyrocketed by 65bps to 11.85% in 2026.
  • Per Business Quant, the three most recent readings for TWST's FCF Margin are 11.85% (Q1 2026), 33.55% (Q4 2025), and 24.48% (Q3 2025).